TABLE 1.
Summary of Baseline Characteristics Among 2102 HIV-Infected Subjects Enrolled in PACTG 219/219C, 1993–2005
| No. HIV Subjects (%) (N = 2102) | |
|---|---|
| Gender | |
| Male | 1040 (49.5%) |
| Female | 1062 (50.5%) |
| Baseline age (yr) | |
| Median | 6.32 yr |
| 0–5.9 yr | 981 (46.7%) |
| 6 yr or more | 1121 (53.3%) |
| Race/Ethnicity | |
| White, nonhispanic | 283 (13.5%) |
| Black, nonhispanic | 1189 (56.6%) |
| Hispanic (any race) | 597 (28.4%) |
| Other/Unknown | 33 (1.6%) |
| Baseline CDC clinical class* | |
| N, A, or B | 1588 (75.5%) |
| C | 514 (24.5%) |
| No. HIV-1 RNA copies at study entry† | |
| Median copies (log10) | 3.9 |
| 0–400 copies | 346 (18.2%) |
| 401–10000 | 669 (35.2%) |
| 10001–100000 | 578 (30.4%) |
| 100001 or more | 306 (16.1%) |
| Missing | 203 |
| CD4+ T-cell % at study entry‡ | |
| Median | 27% |
| 0%–14.9% | 357 (17.0%) |
| 15%–24.9% | 518 (24.6%) |
| 25% or more | 1227 (58.4%) |
| Nadir CD4+ T-cell % prior to third abnormal laboratory result | |
| Median | 17% |
| 0%–14.9% | 838 (39.9%) |
| 15%–24.9% | 725 (34.5%) |
| 25% or more | 539 (25.6%) |
*
If not recorded at study entry, this designation was based on review of clinical diagnoses and in a subset, also laboratory values.
†
Copies per mL plasma; computed as maximum of AUC prior to study entry or closest value to study entry (preferably within 31 d prior).
‡
Closest value to study entry (preferably within 31 d prior).